Which has better earnings and valuation, REPL or DYN?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$247.30M -$3.44 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is REPL or DYN more profitable?

Dyne Therapeutics' return on equity of -58.28% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -102.69% -72.22% Dyne Therapeutics N/A -58.28% -46.77%

Which has better valuation & earnings, REPL or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$247.30M -$3.44 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is REPL or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -102.69% -72.22% Structure Therapeutics N/A -24.91% -23.67%

Do analysts recommend REPL or GMTX?

Replimune Group presently has a consensus target price of $4.88, indicating a potential downside of 57.31%. Given Replimune Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Replimune Group is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 3 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.70 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, REPL or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$247.30M -$3.44 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is REPL or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -102.69% -72.22% Gemini Therapeutics N/A -38.78% -35.88%

Replimune Group (REPL) Competitors

$11.42 +0.24 (+2.15%)

Closing price 04:00 PM Eastern

Extended Trading

$11.06 -0.36 (-3.19%)

As of 08:00 PM Eastern

Compare

REPL vs. ARQT, DYN, GPCR, RCUS, and GMTX

Should you buy Replimune Group stock or one of its competitors? MarketBeat compares Replimune Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Replimune Group include Arcutis Biotherapeutics (ARQT), Dyne Therapeutics (DYN), Structure Therapeutics (GPCR), Arcus Biosciences (RCUS), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical products" industry.

How does Replimune Group compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Arcutis Biotherapeutics has higher revenue and earnings than Replimune Group. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.74	-$16.14M	-$0.03	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

In the previous week, Arcutis Biotherapeutics had 8 more articles in the media than Replimune Group. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 0 mentions for Replimune Group. Arcutis Biotherapeutics' average media sentiment score of 0.48 beat Replimune Group's score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Neutral
Replimune Group	Neutral

Replimune Group has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Replimune Group	N/A	-102.69%	-72.22%

Arcutis Biotherapeutics has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Arcutis Biotherapeutics presently has a consensus target price of $34.00, indicating a potential upside of 29.43%. Replimune Group has a consensus target price of $4.88, indicating a potential downside of 57.31%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Arcutis Biotherapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

92.5% of Replimune Group shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 5.2% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Arcutis Biotherapeutics beats Replimune Group on 12 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Dyne Therapeutics?

Replimune Group (NASDAQ:REPL) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 5.2% of Replimune Group shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Dyne Therapeutics had 14 more articles in the media than Replimune Group. MarketBeat recorded 14 mentions for Dyne Therapeutics and 0 mentions for Replimune Group. Dyne Therapeutics' average media sentiment score of 0.61 beat Replimune Group's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Replimune Group	Neutral
Dyne Therapeutics	Positive

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Replimune Group presently has a consensus target price of $4.88, suggesting a potential downside of 57.31%. Dyne Therapeutics has a consensus target price of $33.85, suggesting a potential upside of 67.06%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.93

Dyne Therapeutics' return on equity of -58.28% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Replimune Group has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Summary

Dyne Therapeutics beats Replimune Group on 12 of the 14 factors compared between the two stocks.

How does Replimune Group compare to Structure Therapeutics?

Replimune Group (NASDAQ:REPL) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Structure Therapeutics' return on equity of -24.91% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Structure Therapeutics	N/A	-24.91%	-23.67%

Replimune Group has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the broader market.

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Structure Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.00 equaled Structure Therapeutics'average media sentiment score.

Company	Overall Sentiment
Replimune Group	Neutral
Structure Therapeutics	Neutral

Replimune Group currently has a consensus target price of $4.88, indicating a potential downside of 57.31%. Structure Therapeutics has a consensus target price of $110.55, indicating a potential upside of 142.37%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Structure Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

Structure Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

Summary

Structure Therapeutics beats Replimune Group on 10 of the 13 factors compared between the two stocks.

How does Replimune Group compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and Replimune Group (NASDAQ:REPL) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Arcus Biosciences currently has a consensus price target of $35.10, indicating a potential upside of 24.64%. Replimune Group has a consensus price target of $4.88, indicating a potential downside of 57.31%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

Arcus Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by insiders. Comparatively, 5.2% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arcus Biosciences had 1 more articles in the media than Replimune Group. MarketBeat recorded 1 mentions for Arcus Biosciences and 0 mentions for Replimune Group. Arcus Biosciences' average media sentiment score of 1.71 beat Replimune Group's score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Arcus Biosciences	Very Positive
Replimune Group	Neutral

Replimune Group has lower revenue, but higher earnings than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	14.34	-$353M	-$3.18	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

Replimune Group has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Arcus Biosciences' return on equity of -68.97% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
Replimune Group	N/A	-102.69%	-72.22%

Summary

Arcus Biosciences beats Replimune Group on 11 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Gemini Therapeutics?

Replimune Group (NASDAQ:REPL) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

In the previous week, Replimune Group's average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.

Company	Overall Sentiment
Replimune Group	Neutral
Gemini Therapeutics	Neutral

Gemini Therapeutics' return on equity of -38.78% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Gemini Therapeutics	N/A	-38.78%	-35.88%

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Replimune Group presently has a consensus target price of $4.88, indicating a potential downside of 57.31%. Given Replimune Group's stronger consensus rating and higher probable upside, equities research analysts plainly believe Replimune Group is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Replimune Group has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the broader market.

Summary

Replimune Group and Gemini Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REPL vs. The Competition

Export

Metric	Replimune Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$923.16M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-3.32	19.75	24.92	23.98
Price / Sales	N/A	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	2.11	8.29	10.79	6.50
Net Income	-$247.30M	$23.85M	$3.56B	$336.88M
7 Day Performance	30.07%	5.21%	1.67%	-0.22%
1 Month Performance	132.59%	2.19%	0.43%	0.77%
1 Year Performance	23.73%	60.99%	32.84%	31.57%

Replimune Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REPL Replimune Group	1.1884 of 5 stars	$11.42 +2.1%	$4.88 -57.3%	+20.6%	$923.16M	N/A	N/A	210	Upcoming Earnings Gap Down
ARQT Arcutis Biotherapeutics	3.9482 of 5 stars	$26.21 flat	$34.00 +29.7%	+92.9%	$3.28B	$376.07M	N/A	150	High Trading Volume
DYN Dyne Therapeutics	2.6044 of 5 stars	$19.80 flat	$33.85 +70.9%	+102.2%	$3.27B	N/A	N/A	100	Analyst Upgrade Gap Down High Trading Volume
GPCR Structure Therapeutics	2.2105 of 5 stars	$44.51 flat	$106.75 +139.8%	+109.4%	$3.16B	N/A	N/A	136
RCUS Arcus Biosciences	3.3674 of 5 stars	$24.39 +0.3%	$35.10 +43.9%	+213.3%	$3.07B	$247M	N/A	500	Positive News High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REPL) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Competitors

REPL vs. ARQT, DYN, GPCR, RCUS, and GMTX

How does Replimune Group compare to Arcutis Biotherapeutics?

Summary

How does Replimune Group compare to Dyne Therapeutics?

Summary

How does Replimune Group compare to Structure Therapeutics?

Summary

How does Replimune Group compare to Arcus Biosciences?

Summary

How does Replimune Group compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Replimune Group (REPL) Competitors

REPL vs. ARQT, DYN, GPCR, RCUS, and GMTX

How does Replimune Group compare to Arcutis Biotherapeutics?

Which has higher earnings & valuation, ARQT or REPL?

Does the media favor ARQT or REPL?

Is ARQT or REPL more profitable?

Which has more volatility and risk, ARQT or REPL?

Do analysts recommend ARQT or REPL?

Do insiders & institutionals have more ownership in ARQT or REPL?

Summary

How does Replimune Group compare to Dyne Therapeutics?

Do institutionals and insiders have more ownership in REPL or DYN?

Does the media prefer REPL or DYN?

Which has better earnings and valuation, REPL or DYN?

Do analysts recommend REPL or DYN?

Is REPL or DYN more profitable?

Which has more risk & volatility, REPL or DYN?

Summary

How does Replimune Group compare to Structure Therapeutics?

Is REPL or GPCR more profitable?

Which has more volatility and risk, REPL or GPCR?

Do institutionals & insiders have more ownership in REPL or GPCR?

Does the media refer more to REPL or GPCR?

Do analysts prefer REPL or GPCR?

Which has better valuation & earnings, REPL or GPCR?

Summary

How does Replimune Group compare to Arcus Biosciences?

Do analysts rate RCUS or REPL?

Which has more volatility & risk, RCUS or REPL?

Do institutionals and insiders believe in RCUS or REPL?

Does the media favor RCUS or REPL?

Which has stronger earnings and valuation, RCUS or REPL?

Is RCUS or REPL more profitable?

Summary

How does Replimune Group compare to Gemini Therapeutics?

Which has higher valuation & earnings, REPL or GMTX?

Does the media refer more to REPL or GMTX?

Is REPL or GMTX more profitable?

Do institutionals & insiders have more ownership in REPL or GMTX?

Do analysts recommend REPL or GMTX?

Which has more risk & volatility, REPL or GMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools